Oncology Business Review (OBR) is a primary information resource dedicated exclusively to the business of oncology. About Us»
(Wall Street Journal Health Blog) July 29, 2010 - An FDA advisory committee’s vote to revoke the approval of Roche-Genentech’s Avastin for treating breast cancer has drawn rough words from a Republican senator. David Vitter of Louisiana called the decision “essentially government rationing.”
read article (paid subscription required) »
(Bloomberg) July 28, 2010 - Dendreon Corp.’s prostate cancer vaccine, Provenge, extended lives by 4.1 months in a study published in the New England Journal of Medicine. The data, released previously, led to the drug’s U.S. approval in April.
read article »
(TheStreet) July 28, 2010 - The ability of Dendreon's Provenge to prolong the survival of prostate cancer patients without having any measurable effect on the tumor is called "surprising" and "hard to understand" in an editorial published Wednesday night in the New England Journal of Medicine.
read article »
![]() |
Our free daily oncology focused e-news service. Subscribe» | Search Archives» | |
Oncology Business Review is our industry trade journal with carefully developed, exclusive oncology industry content. SUBSCRIBE Today!
Our dynamic, eco-friendly companion to our print journal Oncology Business Review. Register for OBR green today. View OBR green.